Don’t miss the presentation of the ctDNA analysis from #DAPHNe , presented on 6/2 by Ada Waks from Dana-Farber’s Breast Oncology Center

📣La X-DOL Academy-First Edition è un progetto di educazione e formazione dedicato ai giovani oncologi e patologi sull’utilizzo di social media, ed in particolare di X, nella comunicazione medica.

🗣️FACULTY:
Saverio Cinieri - Saverio Cinieri
Massimo Di Maio - Massimo Di Maio…

Upcoming early-phase ADC data at #ASCO24 , powered by Raffaele Colombo:

Oncologist’s dream

Converting an immune desert tumor into an inflamed tumor

The SERENA-1 phase 1 trial of camizestrant in ER+/HER2- MBC is published in Annals of Oncology. Among 108 pretreated pts (median: 3 prior lines), camizestrant had an ORR of 15% & mPFS of 5.4 months. Key toxicities: visual effects (56%) and bradycardia (44%). annalsofoncology.org/article/S0923-…

La cancellazione del monologo di #Scurati era #censura
La contestazione disciplinare a #SerenaBortone è un’emergenza democratica

È la #Rai bellezza

Paolo Tarantino Underpowered trial is my guess

I think most patients would have an easy job picking which curve they wanted to be on. #Monarch3 #bcsm

1. 1998: the FDA approves trastuzumab. HER2+ becomes clinically relevant.

2. 2022: T-DXd improves outcomes in HER2-low MBC. HER2-low becomes clinically relevant.

3. 2024: T-DXd improves outcomes in HER2-low + ultralow. HER2-ultralow becomes clinically relevant.

4. Stay tuned

MONARCH 3 final OS results.

Statistically negative (p=0.06), but hard to argue that 13.1 months delta in OS does not denote a clinical benefit.

annalsofoncology.org/article/S0923-…

Does HER2-low expression impact the incidence of CNS disease from breast cancer?

Large analysis (n≃20.000) from the ESME database shows similar incidence and outcomes for brain mets & LMD between HER2-low vs HER2-0 MBC, but higher incidence in HER2+.

Published in ESMO Open 🔥

We are leading a phase 2 trial, called #TRADE , to assess if a brief dose escalation of adjuvant #abemaciclib w/ ongoing endocrine therapy reduces side effects & improves tolerability in patients with early-stage HR-positive and HER2-negative #BreastCancer .
dana-farber.org/clinical-trial…

#ESMOVirtualPlenary : Tune in tomorrow (9/5) for the latest, promising findings for the treatment of metastatic #breastcancer (mBC). Open to everyone, everywhere. 📢 Fuzuloparib w/ or without apatinib in HER2- mBC pts w/ germline BRCA1/2 mutations: A randomised ph III trial.…

Reproductive rights in the United States: acquiescence is not a strategy.

Comment from Dr. Laura Esserman & Douglas Yee MD, as part of our ongoing series on Women's Health

nature.com/articles/s4159…

ESMO - Eur. Oncology Andres Cervantes Ann Partridge MD, MPH Rebecca Dent Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Tom Powles silke gillessen George Pentheroudakis we welcome submissions for another exciting congress in Barcelona in September! Few hours left for submission deadline! OncoAlert Fred Hutchinson Cancer Center Dr. Tom Lynch

Paolo Tarantino G Curigliano MD PhD Exciting. Little known fact from this GU oncologist: I did my med school & residency training at UCLA Health & worked in the Slamon lab under Mark Pegram. Have been closely following the fascinating HER2 story unfold over 25y. Can’t wait for #ASCO24 to see these latest…

DESTINY-Breast06 will be presented on 6/2 at #ASCO24 by my friend & mentor of many years G Curigliano MD PhD. The trial, announced to be positive, may have a major impact on treatment sequencing and on the definition of HER2. Set your alarm clocks early on Sunday, make sure not to miss it.

FDA Approves Noninvasive Stool RNA Screening Test for CRC onclive.com/view/fda-appro… via @onclive

Congratulations to Barbara on becoming the new President of ESTRO! 🎉 Looking forward to seeing the continued growth and development under your leadership. #ESTRO24 IEO